Kaku, Chengzi I. http://orcid.org/0000-0002-9854-8351
Starr, Tyler N. http://orcid.org/0000-0001-6713-6904
Zhou, Panpan http://orcid.org/0000-0001-5740-4303
Dugan, Haley L.
Khalifé, Paul
Song, Ge http://orcid.org/0000-0001-7306-3510
Champney, Elizabeth R.
Mielcarz, Daniel W. http://orcid.org/0000-0001-8784-8386
Geoghegan, James C.
Burton, Dennis R. http://orcid.org/0000-0001-6711-9864
Andrabi, Raiees http://orcid.org/0000-0001-8837-7520
Bloom, Jesse D. http://orcid.org/0000-0003-1267-3408
Walker, Laura M.
Funding for this research was provided by:
Bill and Melinda Gates Foundation (INV-004923)
Article History
Received: 9 November 2022
Accepted: 27 April 2023
First Online: 12 May 2023
Competing interests
: C.I.K. and L.M.W. are former employees and hold shares in Adimab. LLC. P.K., H.L.D., E.R.C., and J.C.G. are current employees and hold shares in Adimab LLC. L.M.W. is a former employee and holds shares in Invivyd Inc. T.N.S. and J.D.B. consult with Apriori Bio. J.D.B. has consulted for Moderna and Merck on viral evolution and epidemiology. D.R.B. is a consultant for IAVI, Invivyd, Adimab, Mabloc, VosBio, Nonigenex, and Radiant. C.I.K. and L.M.W. are inventors on a provisional patent application (No. 63/408,980) describing the SARS-CoV-2 antibodies reported in this work. T.N.S. and J.D.B. may receive a share of intellectual property revenue as inventors on Fred Hutchinson Cancer Center–optioned technology and patents related to deep mutational scanning of viral proteins. The remaining authors declare no competing interests.